Gender Differences With Ibutilide Effectiveness and Safety in Cardioversion of Atrial Fibrillation.
Atrial fibrillation
Atrial flutter
Cardioversion
Gender
Ibutilide
Magnesium sulfate
Journal
The Journal of surgical research
ISSN: 1095-8673
Titre abrégé: J Surg Res
Pays: United States
ID NLM: 0376340
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
25
05
2023
revised:
13
11
2023
accepted:
07
12
2023
pubmed:
6
1
2024
medline:
6
1
2024
entrez:
5
1
2024
Statut:
ppublish
Résumé
Few studies have examined the use of ibutilide in noncardiac surgical populations. Our study considered the effectiveness and safety of ibutilide in cardioversion of atrial fibrillation (AF) in medical and surgical intensive care patients. A retrospective chart review was performed for patients with a confirmed diagnosis of AF who were hemodynamically stable and received ibutilide after the initial diagnosis. Patients were administered 1 mg of ibutilide fumarate intravenous for 10 min with a second dose administered if AF persisted after 30 min. Patients were pretreated with intravenous magnesium sulfate if their blood magnesium level was <2 mg/dL. Fifty seven total female patients and 99 male patients received ibutilide. Females had an 88% conversion rate to normal sinus rhythm (NSR) compared to 68% in males (P = 0.008). A 70% successful return to NSR was observed in patients from all groups pretreated with magnesium sulfate (P = 0.045). One year after discharge, 74% of the patients stayed in the NSR. Within our population, pretreatment with magnesium sulfate followed by ibutilide was associated with increased conversion to NSR. Additionally, we noted that females had a higher conversion rate to NSR compared to males, regardless of whether they were pretreated with magnesium sulfate.
Identifiants
pubmed: 38181644
pii: S0022-4804(23)00648-0
doi: 10.1016/j.jss.2023.12.002
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-17Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.